…
…
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum;…
Worldwide, there are currently nine companies with market capitalizations of $1 trillion or higher. Taiwan Semiconductor Manufacturing (NYSE: TSM) fluctuates…
Its always a great time to invest in quality businesses that can prime your portfolio for long-term growth. Its important…
The world of pharmacenutical stocks has a lot to offer investors. With their resilience in the face of economic issues…
Shares of healthcare company Hims Hers Health ($HIMS) surged on Thursday after a Texas court temporarily paused a case…
Him & Hers Health (NYSE:HIMS) closed up ~10% Thursday after a federal court in Texas administratively closed a case in…
Citi notes that the FDA said in a status report filed in a Texas court that it needs more time…
Shares of Lilly are cratering, but investors may be surprised to learn whats influencing the volatility.…
Shares of Lilly are cratering, but investors may be surprised to learn whats influencing the volatility.…
…
…
Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY)…
…
Eli Lilly’s cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.…
Todays Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), PepsiCo, Inc. (PEP)…
Many investors have a type of acrophobia (the fear of heights). Its not that theyre worried about standing at the…
The drugmaker Ely Lilly (NYSE: LLY) has had a very successful run over the long run. Shares currently trade around…
…
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has helped…
Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.…
Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.…
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound…
The good times arent over, but the peak of the party might be passing.…
The good times arent over, but the peak of the party might be passing.…
…
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
…
The markets perception of the pharmaceutical company has undeniably shifted.…
The markets perception of the pharmaceutical company has undeniably shifted.…
Eli Lilly stock has fallen in the days following the release of its latest earnings numbers.…
Eli Lilly stock has fallen in the days following the release of its latest earnings numbers.…
The company expects to enjoy many GLP-1 tailwinds in 2025.…
Here are the biggest calls on Wall Street on Tuesday.…
Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter revenue…
Hims & Hers Health Earnings Preview…
NEW YORK (dpa-AFX) - Die im März 2023 losgetretene Rally der Eli-Lilly-Aktien ist am Mittwoch…
INDIANAPOLIS (dpa-AFX) - Der US-Pharmahersteller Lilly hat im vergangenen Quartal nicht an das starke erste…
INDIANAPOLIS (dpa-AFX) - Der US-Pharmahersteller Lilly hat dank des Erfolgs seiner Diabetes- und Abnehmmedikamente Mounjaro…
INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Eli Lilly hat im zweiten Quartal einen Umsatz- und Ergebnissprung…
INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Eli Lilly hat im zweiten Quartal einen Umsatz- und Ergebnissprung…
WHITE OAK/INDIANAPOLIS (dpa-AFX) - Der US-Arzneimittelhersteller Eli Lilly kann weiter auf eine Zulassung seines Alzheimermittels…
INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Eli Lilly ist dank gut laufender Geschäfte mit Abnehmmitteln mit…
GREIFSWALD (dpa-AFX) - Die Greifswalder Pharmafirma Cheplapharm ist weiter auf Wachstumskurs. Im Geschäftsjahr 2023 sei ein…
INDIANAPOLS (dpa-AFX) - Der US-Arzneimittelhersteller Lilly muss womöglich noch länger auf eine Zulassung seines Alzheimermittels…
NEW YORK (dpa-AFX Broker) - Das Analysehaus Jefferies hat das Kursziel für Eli Lilly nach…
INDIANAPOLIS (dpa-AFX) - Nach dem Verkaufsstart seines Abnehmmittels traut sich der Pharmakonzern Eli Lilly 2024…
INDIANAPOLIS (dpa-AFX) - Nach dem Verkaufsstart seines Abnehmmittels traut sich der Pharmakonzern Eli Lilly 2024…
NEW YORK (dpa-AFX) - Aktuelle Daten zum Abnehmmittel Zepbound (Tirzepatide) haben den in diesem Jahr bislang…